| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_946bb0e58a06b4019c3ee10d37d64de7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2017-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_040d873b6cf962deb6729a46edd8c8fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_520473cb31043fae968cac8805aa6164 |
| publicationDate |
2019-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110267656-A |
| titleOfInvention |
Use of lasofoxifene to modulate membrane-bound estrogen signaling and methods of treating cancer |
| abstract |
The present invention finds that lasofifene is an antagonist of ER-α36. It not only inhibits the growth of ER‑α36-positive lung, colon and gastric cancer, but also inhibits the growth of acquired or de novo tamoxifen-resistant MCF‑7 cells. Also provided are methods and compositions for the treatment of cancer, comprising use alone or in combination with at least one of gefitinib and/or trastuzumab or functional equivalents thereof and hormone or epidermal growth factor signal transduction pathways In combination with other agents selected from the inhibitors. |
| priorityDate |
2017-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |